TABLE 4.

Emergency admissions certainly consecutive to contraindication or warned against concomitant uses, n = 22

Clinical effect	Drug A	Drug B	Pk/Pd	Identified by clinicians	n (%)	Age, yearMedian (IQR)	Sex ratio (F/M)
ALL					22	84 (80–88)	0.59
Contraindication					7 (32)	84 (79–87)	0.43
LQTS a	Amiodarone	Escitalopram	PD	No	2 (9)
	Amisulpride	Hydroxyzine	PD	No	1 (5)
	Escitalopram	Hydroxychloroquine	PD	No	1 (5)
Heart failure	Bisoprolol	Flecainide	PD	No	2 (9)
Drug overdose	Alfuzosin b	Ketoconazole	PK	No	1 (5)
Warned against					15 (68)	84 (81–89)	0.67
Hemorrhage	Apixaban	Diclofenac	PD	Yes c	2 (9)
	Diclofenac	Enoxaparin	PD	No	1 (5)
	Fluconazole	Rivaroxaban	PK	No	1 (5)
	Dabigatran	Ketoprofen	PD	Yes	1 (5)
	Diclofenac	Fluindione	PD	No	1 (5)
Drug overdose	Furosemide	Lithium d	PK	No	2 (9)
	Ketoprofen	Lithium d	PK	Yes	1 (5)
	Lamotrigine	Valproic acid e	PK	Yes	1 (5)
Apixaban ineffectiveness	Apixaban	Phenobarbital	PK	No	1 (5)
Hyponatremia	Oxcarbazepine	Sertraline	PD	No	1 (5)
Hypotension	Silodosin	Urapidil	PD	Yes	1 (5)
LQTS	Amiodarone	Domperidone	PD	Yes	1 (5)
Psychotic disorders	Cyamemazine	Levodopa	PD	Yes	1 (5)

Abbreviations: DDI, drug‐drug interaction; IQR, interquartile range; LQTS, long QT syndrome; PD, pharmacodynamic; PK, pharmacokinetic.

^a Long QT syndrome.

^b Alfuzosin overdose.

^c Only one of these two DDI was identified by clinicians.

^d Lithium overdose.

^e Lamotrigine overdose.